Show simple item record

dc.contributor.authorHollfelder, Gabrielle
dc.contributor.authorLaRochelle, Sophie
dc.contributor.authorNeumann, Bernd
dc.date.accessioned2017-05-03T18:57:34Z
dc.date.available2017-05-03T18:57:34Z
dc.date.issued2017
dc.identifier.urihttp://hdl.handle.net/1951/69159
dc.descriptionEpithelial ovarian cancer accounts for 90% of ovarian cancers, is the most lethal gynecological cancer, and the fifth-most common cause of cancer-related deaths in women in the United States(6). In 2016, there were an esitmated 22,280 new cases in the U.S. and the overall survival rate at 5 years is 46.2%(3). About 10% of cases are heriditary (4). Clinical trials have shown that the efficacy of more traditional platinum-based drugs are increased when combined with a taxane-based drug. Docetaxel, commercially Taxotere, is a taxane that has been in use since the mid-1990s and is used to treat many forms of cancer including ovarian but also; breast, lung, head and neck, gastric and prostrate carcinomas. Taxotere is derived from the needles of the European Yew tree (Taxus baccata) by a semisynthetic process(1)and like other taxane-based drugs, binds to microtubules during mitosis leading to apoptosis and cell death(2).en_US
dc.language.isoen_USen_US
dc.titleTaxotere as a Treatment for Ovarian Epithelial Carcinomaen_US
dc.typeLearning Objecten_US
dc.typePresentationen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record